Resources, Production Scales and Time Required for Producing RNA Vaccines for the Global Pandemic Demand

Resources, Production Scales and Time Required for Producing RNA Vaccines for the Global Pandemic Demand

To overcome pandemics, such as COVID-19, vaccines are urgently needed at very high volumes. Here we assess the techno-economic feasibility of producing RNA vaccines for the demand associated with a global vaccination campaign. Production process performance is assessed for three messenger RNA (mRNA)...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy:	Zoltán Kis, Cleo Kontoravdi, Robin Shattock, Nilay Shah
Format:	Artykuł
Język:	English
Wydane:	MDPI AG 2020-12-01
Seria:	Vaccines
Hasła przedmiotowe:	RNA vaccines mRNA vaccines saRNA vaccines pandemic-response vaccine production COVID-19 production process modelling
Dostęp online:	https://www.mdpi.com/2076-393X/9/1/3

Podobne zapisy

A self-amplifying RNA vaccine provides protection in a murine model of bubonic plague
od: Robin John Shattock, i wsp.
Wydane: (2023-11-01)

Vaccines’ New Era-RNA Vaccine
od: Wenshuo Zhou, i wsp.
Wydane: (2023-08-01)

Advancing mRNA technologies for therapies and vaccines: An African context
od: Dylan Kairuz, i wsp.
Wydane: (2022-10-01)

The Importance of RNA-Based Vaccines in the Fight against COVID-19: An Overview
od: Bruna Aparecida Souza Machado, i wsp.
Wydane: (2021-11-01)

Evaluation of a self-amplifying mRNA reporter vaccine in explant models of broiler chickens
od: Janne Snoeck, i wsp.
Wydane: (2023-11-01)

The Current Landscape of mRNA Vaccines Against Viruses and Cancer–A Mini Review
od: Reese Jalal Ladak, i wsp.
Wydane: (2022-05-01)

Advances in saRNA Vaccine Research against Emerging/Re-Emerging Viruses
od: Yalan Liu, i wsp.
Wydane: (2023-06-01)

In Vitro Transcribed RNA-Based Platform Vaccines: Past, Present, and Future
od: Alexey D. Perenkov, i wsp.
Wydane: (2023-10-01)

Editorial: RNA vaccines for prevalent and newly emerging diseases
od: César López-Camacho, i wsp.
Wydane: (2024-08-01)

Development of mRNA rabies vaccines
od: Zixin Fang, i wsp.
Wydane: (2024-12-01)

A Lipid Nanoparticle-Formulated Self-Amplifying RNA Rift Valley Fever Vaccine Induces a Robust Humoral Immune Response in Mice
od: Paul K. Kitandwe, i wsp.
Wydane: (2024-09-01)

Production, Characterization, and Assessment of Permanently Cationic and Ionizable Lipid Nanoparticles for Use in the Delivery of Self-Amplifying RNA Vaccines
od: Dylan Kairuz, i wsp.
Wydane: (2023-04-01)

Efficient mRNA Delivery with mRNA Lipoplexes Prepared Using a Modified Ethanol Injection Method
od: Min Tang, i wsp.
Wydane: (2023-04-01)

Advantages of Broad-Spectrum Influenza mRNA Vaccines and Their Impact on Pulmonary Influenza
od: Ziqi Cheng, i wsp.
Wydane: (2024-12-01)

Post-RNA (mRNA) Vaccination Myocarditis: CMR Features
od: Karuna M. Das, i wsp.
Wydane: (2022-04-01)

RNA-based vaccines – types, strategies of delivery and overview of RNA vaccines
od: Barbara Rusinowska, i wsp.
Wydane: (2022-08-01)

Immunogenicity of HIV-1 <i>Env</i> mRNA and <i>Env-Gag</i> VLP mRNA Vaccines in Mice
od: Qi Ma, i wsp.
Wydane: (2025-01-01)

An mRNA vaccine against rabies provides strong and durable protection in mice
od: Miao Li, i wsp.
Wydane: (2023-10-01)

Opportunities and challenges to implementing mRNA-based vaccines and medicines: lessons from COVID-19
od: Shehzad M. Iqbal, i wsp.
Wydane: (2024-08-01)

Safety and immunogenicity of an mRNA-1273 vaccine booster in adolescents
od: Amparo L. Figueroa, i wsp.
Wydane: (2025-12-01)

mRNA cancer vaccines from bench to bedside: a new era in cancer immunotherapy
od: Alireza Shariati, i wsp.
Wydane: (2024-12-01)

RETRACTED ARTICLE: An overview on mRNA-based vaccines to prevent monkeypox infection
od: Mohammad Natami, i wsp.
Wydane: (2024-03-01)

Serological findings following the second and third SARS‐CoV‐2 vaccines in lung transplant recipients
od: Enikő Bárczi, i wsp.
Wydane: (2022-08-01)

The Pivotal Role of Chemical Modifications in mRNA Therapeutics
od: Albert Liu, i wsp.
Wydane: (2022-07-01)

COVID-19 mRNA Vaccines: The Molecular Basis of Some Adverse Events
od: Girolamo Giannotta, i wsp.
Wydane: (2023-03-01)

Concomitant administration of seasonal influenza and COVID-19 mRNA vaccines
od: Teresa Aydillo, i wsp.
Wydane: (2024-12-01)

Effectiveness of mRNA COVID-19 Vaccination on SARS-CoV-2 Infection and COVID-19 in Sicily over an Eight-Month Period
od: Emanuele Amodio, i wsp.
Wydane: (2022-03-01)

Anion exchange HPLC monitoring of mRNA in vitro transcription reactions to support mRNA manufacturing process development
od: Emma N. Welbourne, i wsp.
Wydane: (2024-03-01)

Universal Flu mRNA Vaccine: Promises, Prospects, and Problems
od: Andrei A. Deviatkin, i wsp.
Wydane: (2022-04-01)

An Overview on the Development of mRNA-Based Vaccines and Their Formulation Strategies for Improved Antigen Expression In Vivo
od: Md. Motiar Rahman, i wsp.
Wydane: (2021-03-01)

Editorial: Building public confidence in innovative mRNA vaccines
od: Jia Hu, i wsp.
Wydane: (2025-01-01)

mRNA-Based Vaccine for COVID-19: They Are New but Not Unknown!
od: Vivek P. Chavda, i wsp.
Wydane: (2023-02-01)

Advances in nucleic acid-based cancer vaccines
od: Hung-Chun Liao, i wsp.
Wydane: (2025-01-01)

Safety and Efficacy of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Different Vaccines at Phase 3
od: Yu-Jing Fan, i wsp.
Wydane: (2021-09-01)

Stability Modelling of mRNA Vaccine Quality Based on Temperature Monitoring throughout the Distribution Chain
od: Zoltán Kis
Wydane: (2022-02-01)

A Multicenter Cohort Study on the Adverse Effects Evaluation After Messenger RNA COVID-19 Vaccination Among Pregnant Healthcare Employees in Penang General Hospitals
od: Ann Lisa Arulappen, i wsp.
Wydane: (2022-05-01)

mRNA Technology and Mucosal Immunization
od: Antonio Toniolo, i wsp.
Wydane: (2024-06-01)

Strategy of developing nucleic acid-based universal monkeypox vaccine candidates
od: Dimitri Papukashvili, i wsp.
Wydane: (2022-10-01)

Dendrimer-Mediated Delivery of DNA and RNA Vaccines
od: Lyubov A. Kisakova, i wsp.
Wydane: (2023-03-01)

The Effect of Vaccine Type and SARS-CoV-2 Lineage on Commercial SARS-CoV-2 Serologic and Pseudotype Neutralization Assays in mRNA Vaccine Recipients
od: Nicole V. Tolan, i wsp.
Wydane: (2022-04-01)